Evidence map›Paper›PMID 31417673›Full record

SynthesisAntimicrobial resistance and infection control2019

Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review.

Xuemei Zhen, Cecilia Stålsby Lundborg, Xueshan Sun, Xiaoqian Hu, Hengjin Dong

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Antimicrobial resistance and infection control, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 163 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

163 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Thymol and carvacrol againstFrontiers in pharmacology · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Characterization of anAntibiotics (Basel, Switzerland) · 2026
    Article
  18. Article
  19. Article
  20. Article

103 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xuemei Zhen1Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, 866 Yuhangtang Road, Hangzhou, 310058 Zhejiang China.
Cecilia Stålsby Lundborg2Global Health-Health Systems and Policy (HSP): Medicines, focusing antibiotics, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.
Xueshan Sun1Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, 866 Yuhangtang Road, Hangzhou, 310058 Zhejiang China.
Xiaoqian Hu1Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, 866 Yuhangtang Road, Hangzhou, 310058 Zhejiang China.
Hengjin Dong1Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, 866 Yuhangtang Road, Hangzhou, 310058 Zhejiang China.ORCID 0000-0002-5064-7297

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Antibiotic resistance (ABR) is one of the biggest threats to global health. Infections by ESKAPE ( Objective: This study aims to systematically review and evaluate the evidence of the economic consequences of ABR or MDR ESKAPE organisms compared with susceptible cases or control patients without infection/colonization in order to determine the impact of ABR on economic burden. Methods: Both English-language databases and Chinese-language databases up to 16 January, 2019 were searched to identify relevant studies assessing the economic burden of ABR. Studies reported hospital costs (charges) or antibiotic cost during the entire hospitalization and during the period before/after culture among patients with ABR or MDR ESKAPE organisms were included. The costs were converted into 2015 United States Dollars. Disagreements were resolved by a third reviewer. Results: Of 13,693 studies identified, 83 eligible studies were included in our review. The most studied organism was Conclusions: ABR in ESKAPE organisms is not always, but usually, associated with significantly higher economic burden. The results without significant differences may lack statistical power to detect a significant association. In addition, study design which controls for severity of illness and same empirical antibiotic therapy in the two groups would be expected to bias the study towards a similar, even negative result. The review also highlights key areas where further research is needed.

Indexed as

Drug Resistance, Multiple, BacterialAcinetobacter baumanniiAnti-Bacterial AgentsEnterococcusEscherichia coliGram-Negative Bacterial InfectionsGram-Positive Bacterial InfectionsHospital CostsHumansKlebsiella pneumoniaePseudomonas aeruginosaStaphylococcus aureusAnti-Bacterial AgentsA. baumanniiAntibiotic resistanceE. coliEconomic burdenEnterococcusESKAPE organismK. pneumoniaeP. aeruginosaS. aureus

Identifiers

PMID31417673
PMCPMC6692939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.